0UNL Stock Overview
A biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Nektar Therapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.11 |
| 52 Week High | US$1.93 |
| 52 Week Low | US$0.44 |
| Beta | 0.61 |
| 11 Month Change | -17.13% |
| 3 Month Change | -11.85% |
| 1 Year Change | 136.26% |
| 33 Year Change | -90.13% |
| 5 Year Change | -94.83% |
| Change since IPO | -97.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0UNL | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 6.8% | 5.0% | 2.2% |
| 1Y | 136.3% | 2.5% | 8.8% |
Return vs Industry: 0UNL exceeded the UK Pharmaceuticals industry which returned 2.2% over the past year.
Return vs Market: 0UNL exceeded the UK Market which returned 8.3% over the past year.
Price Volatility
| 0UNL volatility | |
|---|---|
| 0UNL Average Weekly Movement | 9.7% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0UNL's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0UNL's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 137 | Howard Robin | www.nektar.com |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system’s natural ability to fight cancer. The company serves its clients in the United States and internationally.
Nektar Therapeutics Fundamentals Summary
| 0UNL fundamental statistics | |
|---|---|
| Market cap | US$193.68m |
| Earnings (TTM) | -US$168.30m |
| Revenue (TTM) | US$93.14m |
2.1x
P/S Ratio-1.2x
P/E RatioIs 0UNL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0UNL income statement (TTM) | |
|---|---|
| Revenue | US$93.14m |
| Cost of Revenue | US$29.99m |
| Gross Profit | US$63.15m |
| Other Expenses | US$231.45m |
| Earnings | -US$168.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | 67.80% |
| Net Profit Margin | -180.70% |
| Debt/Equity Ratio | 200.1% |
How did 0UNL perform over the long term?
See historical performance and comparison